サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1696289

人工膵臓システムの世界市場（2025年～2033年）

Global Artificial Pancreas System Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
人工膵臓システムの世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の人工膵臓システムの市場規模は、2024年に4億5,697万米ドルに達し、2033年までに63億470万米ドルに達すると予測され、予測期間の2025年～2033年にCAGRで30.0%の成長が見込まれます。

人工膵臓システムは、1型糖尿病患者の血糖制御を自動化する医療機器です。持続血糖モニター、インスリンポンプ、先進の制御アルゴリズムが含まれます。このシステムは健康な膵臓の機能を模倣し、最適な血糖値を確保し、高血糖や低血糖のリスクを低減します。糖尿病管理と患者の利便性を向上させ、手動でのインスリン投与の必要性を最小化します。

市場力学

促進要因と抑制要因

糖尿病の有病率の上昇

世界の糖尿病の有病率、特に1型糖尿病の有病率が人工膵臓システム市場を牽引しています。多くの糖尿病患者が継続的な血糖値管理を必要としており、自動化ソリューションの需要につながっています。センサー技術の進歩によりインスリン投与が改善され、AI駆動のアルゴリズムが効率的な個別化された糖尿病管理ソリューションを提供することで市場成長に寄与しています。

例えば、IDFによると、2045年までに糖尿病の有病率は46%増加し、90%超が2型糖尿病になると予測しています。この増加の要因は、都市化、高齢化、身体活動の低下、過体重や肥満の増加で、これらは社会経済的、人口統計的、環境的、遺伝的要因によって悪化しています。

したがって、糖尿病の有病率の増加は、人工膵臓デバイスシステムの需要を促進します。この需要と都市化やライフスタイルに関連した危険因子により、先進のグルコース管理ソリューションが必要とされ、自動インスリン投与の市場拡大につながります。

人工膵臓システムの高いコスト

人工膵臓システムは、糖尿病管理における潜在的な恩恵にもかかわらず、特に低中所得国において市場の拡大の大きな障壁に直面しています。先進のコンポーネントの高いコスト、限られた償還政策、高い維持費がさらに採用を制限し、普及を制限しています。例えば、Tandem t:slim X2 Pump（Control-IQ付き）の価格は約4,000米ドルで、通常は保険で価格の80%がカバーされます。トランスミッターやセンサーなど、Dexcom G6 CGMの消耗品にかかる追加のコストは高額になる可能性があります。

当レポートでは、世界の人工膵臓システム市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

第3章 市場のハイライトと戦略的ポイント

  • 主要動向と将来の予測
  • 抜粋：デバイスタイプ別
  • 抜粋：エンドユーザー別
  • 抜粋：地域別

第4章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病の有病率の上昇
      • ウェアラブルデバイスやAI駆動医療機器の採用の拡大
    • 抑制要因
      • 人工膵臓システムの高いコスト
      • 厳しい規制要件と承認の遅延
    • 機会
      • 個別化された糖尿病管理に向けたAIと機械学習の統合
    • 影響の分析

第5章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第6章 デバイスタイプ別

  • 基準値サスペンドデバイスシステム
  • インスリンのみのシステム
  • デュアルホルモンシステム

第7章 エンドユーザー別

  • 病院
  • 診療所
  • 在宅ケア環境
  • 外来手術センター

第8章 地域市場の分析と成長機会

第9章 イントロダクション

  • 北米
    • 主な地域特有の動向
      • 米国
      • カナダ
  • 欧州
    • 主な地域特有の動向
      • ドイツ
      • 英国
      • フランス
      • スペイン
      • イタリア
      • その他の欧州
  • ラテンアメリカ
    • 主な地域特有の動向
      • メキシコ
      • ブラジル
      • アルゼンチン
      • その他のラテンアメリカ
  • アジア太平洋
    • 主な地域特有の動向
      • 中国
      • インド
      • 日本
      • 韓国
      • その他のアジア太平洋
  • 中東・アフリカ
    • 主な地域特有の動向

第10章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
    • 市場シェア分析とポジショニングマトリクス
    • 戦略的パートナーシップ、合併・買収
    • 製品ポートフォリオとイノベーションにおける主な発展
    • 企業ベンチマーク

第11章 企業プロファイル

  • Medtronic Plc
  • Tandem Diabetes Care, Inc
  • Beta Bionics
  • Insulet Corporation
  • Diabeloop
  • Inreda Diabetic BV
  • Nikkiso Co., Ltd (LIST NOT EXHAUSTIVE)

第12章 前提条件と調査手法

第13章 付録

目次
Product Code: MD9415

The global artificial pancreas system market reached US$ 456.97 million in 2024 and is expected to reach US$ 6304.70 million by 2033, growing at a CAGR of 30.0% during the forecast period 2025-2033.

Artificial pancreas system is a medical device that automates blood glucose control in type 1 diabetes patients. It includes a continuous glucose monitor, insulin pump, and advanced control algorithm. This system mimics the function of a healthy pancreas, ensuring optimal blood sugar levels and reducing the risk of hyperglycemia and hypoglycemia. It improves diabetes management and patient convenience and minimizes the need for manual insulin administration.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The global diabetes prevalence, particularly type 1, is driving the artificial pancreas system market. Many diabetes patients need continuous blood glucose management, leading to a demand for automated solutions. Advancements in sensor technology improved insulin delivery, and AI-driven algorithms are contributing to market growth by offering efficient, personalized diabetes management solutions.

For instance, according to International Diabetes Foundation by 2045, IDF projections indicate a 46% increase in diabetes prevalence, with over 90% of individuals having type 2 diabetes. Factors contributing to this increase include urbanization, an aging population, decreased physical activity, and an increase in overweight and obesity, which are exacerbated by socio-economic, demographic, environmental, and genetic factors.

Hence, an increase in the prevalence of diabetes will drive demand for artificial pancreas device systems. This demand, coupled with urbanization and lifestyle-related risk factors, necessitates advanced glucose management solutions, leading to market expansion for automated insulin delivery.

High Cost of Artificial Pancreas Systems

Artificial pancreas systems, despite their potential benefits in diabetes management, face significant barriers to market expansion, particularly in low- and middle-income countries. The high cost of advanced components, limited reimbursement policies, and high maintenance costs further restrict adoption, limiting their widespread use. For instance, The Tandem t:slim X2 pump with Control-IQ costs around $4,000, with insurance typically covering 80% of the cost. Additional costs for Dexcom G6 CGM supplies, such as a transmitter and sensors, can be significant.

Segment Analysis

The global artificial pancreas system market is segmented based on device type, end-user, and region.

Device Type:

The threshold suspend device systems from the device type segment is expected to dominate the artificial pancreas system market with the highest market share

The threshold suspend and predictive suspend systems are tools that temporarily suspend insulin delivery when blood glucose levels drop below a pre-set level. These systems calculate blood glucose levels and stop delivering insulin before they reach too low. They do not automatically increase insulin doses. Storing insulin at the right moment can help prevent low blood sugar, or hypoglycemia, in individuals with type 1 diabetes. These systems may also assist those who develop hypoglycemia overnight, especially children.

The rise in diabetes, particularly type 1, is driving the adoption of Threshold Suspend Device Systems. This is driven by increased awareness of hypoglycemia risks and the need for automated insulin delivery systems. Technological advancements, regulatory approvals, healthcare expenditure, and expanded reimbursement policies in developed regions contribute to the adoption of these life-saving devices.

Geographical Analysis

North America is expected to hold a significant position in the artificial pancreas system market with the highest market share

North America dominates the threshold suspend device systems market due to advanced healthcare infrastructure, high diabetes management technologies, and key market players. The region's large type 1 diabetes population drives demand for automated insulin delivery solutions. Benefits from reimbursement policies, continuous glucose monitoring awareness, and technological advancements in insulin pumps drive market growth. Government initiatives, increased healthcare expenditure, and personalized medicine focus contribute to the growing adoption of Threshold Suspend Device Systems in North America.

Moreover, FDA approvals are also a significant factor that helps the region to grow during the forecast period. For instance, in May 2024, The U.S. Food and Drug Administration (FDA) approved an artificial pancreas developed by University of Cambridge researchers for use by individuals with type 1 diabetes, including during pregnancy, marking the first time the FDA has authorized the use of this life-changing app during pregnancy.

Moreover, in May 2023, the FDA approved the iLet Insulin-Only Bionic Pancreas System for individuals aged 6 and above with type 1 diabetes, an artificial pancreas system that autonomously determines and delivers insulin doses.

Competitive Landscape

The major global players in the artificial pancreas system market include Medtronic Plc, Tandem Diabetes Care, Inc., Beta Bionics, Insulet Corporation, Diabeloop, Inreda Diabetic B.V., and Nikkiso Co., Ltd among others.

Key Developments

  • In April 2024, the NHS launched a world-first initiative for tens of thousands of children and adults with type 1 diabetes in England, which will use an 'artificial pancreas' to monitor blood glucose levels and automatically adjust insulin dosage.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial pancreas system market report delivers a detailed analysis with 45key tables, more than 40 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

3. Market Highlights and Strategic Takeaways

  • 3.1. Key Trends and Future Projections
  • 3.2. Snippet by Device Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetes
      • 4.1.1.2. Growing Adoption of Wearable and AI-driven Healthcare Devices
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Artificial Pancreas Systems
      • 4.1.2.2. Stringent Regulatory Requirements and Approval Delays
    • 4.1.3. Opportunity
      • 4.1.3.1. Integration of AI and Machine Learning for Personalized Diabetes Management
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Device Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 6.1.2. Market Attractiveness Index, By Device Type
  • 6.2. Threshold Suspend Device Systems*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Insulin-only Systems
  • 6.4. Dual Hormone Systems

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Clinics
  • 7.4. Homecare Settings
  • 7.5. Ambulatory Surgical Centers

8. Regional Market Analysis and Growth Opportunities

9. Introduction

  • 9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.1. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Spain
      • 9.3.5.5. Italy
      • 9.3.5.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Mexico
      • 9.4.5.2. Brazil
      • 9.4.5.3. Argentina
      • 9.4.5.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. South Korea
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
    • 10.1.1. Market Share Analysis and Positioning Matrix
    • 10.1.2. Strategic Partnerships, Mergers & Acquisitions
    • 10.1.3. Key Developments in Product Portfolios and Innovations
    • 10.1.4. Company Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.1.1. Geographical Revenue Shares
      • 11.1.3.1.1.1. Revenue Forecasts
      • 11.1.3.1.2. Key Developments
      • 11.1.3.1.2.1. Mergers & Acquisitions
      • 11.1.3.1.2.2. Key Product Development Activities
      • 11.1.3.1.2.3. Regulatory Approvals, etc.
      • 11.1.3.1.3. SWOT Analysis
  • 11.2. Tandem Diabetes Care, Inc
  • 11.3. Beta Bionics
  • 11.4. Insulet Corporation
  • 11.5. Diabeloop
  • 11.6. Inreda Diabetic B.V
  • 11.7. Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us